中国合理用药探索2024,Vol.21Issue(5) :1-4.DOI:10.3969/j.issn.2096-3327.2024.05.001

新型冠状病毒感染相关静脉血栓栓塞症的防治

Prevention and Treatment of Venous Thromboembolism Associated with Corona Virus Disease(COVID-19)

樊欣 丁征
中国合理用药探索2024,Vol.21Issue(5) :1-4.DOI:10.3969/j.issn.2096-3327.2024.05.001

新型冠状病毒感染相关静脉血栓栓塞症的防治

Prevention and Treatment of Venous Thromboembolism Associated with Corona Virus Disease(COVID-19)

樊欣 1丁征2
扫码查看

作者信息

  • 1. 南部县人民医院,南充 637300
  • 2. 中国医学科学院阜外医院,北京 100037
  • 折叠

摘要

新型冠状病毒感染(COVID-19)可通过多种机制引发血栓并发症,其中静脉血栓栓塞症(VTE)是导致COVID-19住院患者死亡或预后不佳的重要原因之一.COVID-19患者的静脉血栓预防需权衡VTE及出血风险.COVID-19患者可能会有凝血功能异常情况,而脏器微血栓、抗凝药物的使用可能会增加出血风险,加重病情.此外,抗凝不充分也会增加重症COVID-19患者的死亡率.因此,尽早启动风险评估、选择适宜的预防和治疗措施对于改善患者预后至关重要.

Abstract

Corona virus disease(COVID-19)can induce thrombotic complications through a variety of mechanisms,among which venous thromboembolism(VTE)is one of the important causes of death or poor prognosis in hospitalized patients with COVID-19.Venous thromboprophylaxis in COVID-19 patients should be used based on the risks of VTE and bleeding.Patients with COVID-19 may have coagulation disorders,which may be exacerbated by organ microthrombi.Anticoagulants may increase the risk of bleeding.In addition,inadequate anticoagulation may lead to increased mortality in critically ill COVID-19 patients.Therefore,early initiation of risk assessment and selection of appropriate preventive and treatment measures are essential to improve patient outcomes.

关键词

新型冠状病毒感染/静脉血栓栓塞症/血栓预防/防治/并发症

Key words

corona virus disease 19/venous thromboembolism/thrombosis prophylaxis/prevention and treatment/complications

引用本文复制引用

基金项目

阜院项目(T2023-ZX037)

出版年

2024
中国合理用药探索
中国执业药师协会

中国合理用药探索

影响因子:0.62
ISSN:2096-3327
段落导航相关论文